Emergent Biosolutions Statistics
Emergent Biosolutions (ER4) Stock Statistics & Valuation Metrics
Total Valuation
Emergent Biosolutions has a market cap or net worth of CHF 258.88M. The enterprise value is CHF 675.38M.
- Market Cap
- CHF 258.88M
- Enterprise Value
- CHF 675.38M
Share Statistics
Emergent Biosolutions has 51,415,180 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 51,415,180
- Owned by Insiders
- 5.29%
- Owned by Institutions
- 57.49%
Financial Efficiency
Emergent Biosolutions’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 5.90%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- 5.90%
- Return on Capital Employed (ROCE)
- 0.09
- Revenue Per Employee
- 825.44K
- Profits Per Employee
- 58.44K
- Employee Count
- 900
- Asset Turnover
- 0.56
- Inventory Turnover
- 1.14
Valuation Ratios
The current PE Ratio of Emergent Biosolutions is -1.20. Emergent Biosolutions’s PEG ratio is -0.06.
- PE Ratio
- -1.20
- PS Ratio
- 0.48
- PB Ratio
- 0.99
- Price to FCF
- 1.65
- Price to Operating Cash Flow
- 1.55
- PEG Ratio
- -0.06
Income Statement
In the last 12 months, Emergent Biosolutions had revenue of 742.90M and earned 52.60M in profits. Earnings per share was 0.98.
- Revenue
- 742.90M
- Gross Profit
- 350.60M
- Operating Income
- 110.20M
- Pretax Income
- 82.80M
- Net Income
- 52.60M
- EBITDA
- 237.90M
- Earnings Per Share (EPS)
- 0.98
Cash Flow
In the last 12 months, operating cash flow was 200.10M and capital expenditures -11.70M, giving a free cash flow of 188.40M billion.
- Operating Cash Flow
- 200.10M
- Free Cash Flow
- 188.40M
- Free Cash Flow per Share
- 3.67
Dividends & Yields
Emergent Biosolutions pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 60.62%
- Earnings Yield
- -84.07%
Stock Price Statistics
- Beta
- -0.18
- 52-Week Price Change
- 29.46%
- 50-Day Moving Average
- 3.91
- 200-Day Moving Average
- 3.91
- Relative Strength Index (RSI)
- 89.82
- Average Volume (3m)
- ―
Important Dates
Emergent Biosolutions upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 02, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Emergent Biosolutions as a current ratio of 5.01, with Debt / Equity ratio of 109.47%
- Current Ratio
- 5.01
- Quick Ratio
- 2.41
- Debt to Market Cap
- 0.87
- Net Debt to EBITDA
- 1.54
- Interest Coverage Ratio
- 1.86
Taxes
In the past 12 months, Emergent Biosolutions has paid 30.20M in taxes.
- Income Tax
- 30.20M
- Effective Tax Rate
- 0.36
Enterprise Valuation
Emergent Biosolutions EV to EBITDA ratio is -5.48, with an EV/FCF ratio of 3.41.
- EV to Sales
- 0.99
- EV to EBITDA
- -5.48
- EV to Free Cash Flow
- 3.41
- EV to Operating Cash Flow
- 3.21
Balance Sheet
Emergent Biosolutions has CHF 175.70M in cash and marketable securities with CHF 507.70M in debt, giving a net cash position of -CHF 332.00M billion.
- Cash & Marketable Securities
- CHF 175.70M
- Total Debt
- CHF 507.70M
- Net Cash
- -CHF 332.00M
- Net Cash Per Share
- -CHF 6.46
- Tangible Book Value Per Share
- CHF 1.18
Margins
Gross margin is 41.60%, with operating margin of -25.96%, and net profit margin of -40.16%.
- Gross Margin
- 41.60%
- Operating Margin
- -25.96%
- Pretax Margin
- -36.97%
- Net Profit Margin
- -40.16%
- EBITDA Margin
- -18.06%
- EBIT Margin
- -31.61%
Analyst Forecast
The average price target for Emergent Biosolutions is CHF 8.14, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- CHF 8.14
- Price Target Upside
- 61.56% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 2
- Revenue Growth Forecast
- -23.26%
- EPS Growth Forecast
- -432.87%
Scores
- Smart Score
- 5
- AI Score
- ―
